- Home
- SF vs ROIV Comparison
SF vs ROIV Comparison
Compare SF & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SF
- ROIV
- Stock Information
- Founded
- SF 1890
- ROIV 2014
- Country
- SF United States
- ROIV United Kingdom
- Employees
- SF N/A
- ROIV N/A
- Industry
- SF Investment Bankers/Brokers/Service
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- SF Finance
- ROIV Health Care
- Exchange
- SF Nasdaq
- ROIV Nasdaq
- Market Cap
- SF 8.5B
- ROIV 8.4B
- IPO Year
- SF N/A
- ROIV N/A
- Fundamental
- Price
- SF $85.13
- ROIV $10.15
- Analyst Decision
- SF Hold
- ROIV Buy
- Analyst Count
- SF 8
- ROIV 4
- Target Price
- SF $105.71
- ROIV $17.50
- AVG Volume (30 Days)
- SF 1.1M
- ROIV 8.0M
- Earning Date
- SF 04-23-2025
- ROIV 05-29-2025
- Dividend Yield
- SF 2.16%
- ROIV N/A
- EPS Growth
- SF 46.03
- ROIV N/A
- EPS
- SF 6.25
- ROIV N/A
- Revenue
- SF $4,944,918,000.00
- ROIV $122,585,000.00
- Revenue This Year
- SF $12.84
- ROIV N/A
- Revenue Next Year
- SF $9.95
- ROIV N/A
- P/E Ratio
- SF $13.62
- ROIV N/A
- Revenue Growth
- SF 14.36
- ROIV 140.04
- 52 Week Low
- SF $73.27
- ROIV $8.73
- 52 Week High
- SF $120.64
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- SF 43.24
- ROIV 50.07
- Support Level
- SF $82.79
- ROIV $9.90
- Resistance Level
- SF $86.63
- ROIV $10.26
- Average True Range (ATR)
- SF 4.95
- ROIV 0.47
- MACD
- SF 0.26
- ROIV 0.06
- Stochastic Oscillator
- SF 50.19
- ROIV 92.81
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.